rituximab
rituximab
Overview
Rituximab is a chimeric monoclonal antibody used as a B-cell–depleting therapeutic agent. It is widely recognized for targeting CD20 on B lymphocytes, leading to depletion of circulating and tissue B cells and thereby modulating antibody-mediated and B-cell–driven immune responses. Because of this mechanism, rituximab has become an important treatment in hematologic malignancies and a range of immune-mediated diseases.
In biomedical research, rituximab is frequently discussed in the context of B-cell biology, immunosuppression, and combination therapy. Its clinical effects are often evaluated alongside agents such as glucocorticoid, cyclophosphamide, bendamustine, vincristine, doxorubicin, cytarabine, etoposide, ifosfamide, and other immunomodulators. More recently, studies have also examined its relationship to vaccine responsiveness, infection risk, and B-cell monitoring, including CD19+ B-cells as a pharmacodynamic marker of B-cell depletion.
Recent Publications Focus
Below is a summary of the newest research publications targeting rituximab (sorted by publication date).
Recent research demonstrates rituximab's continued therapeutic value across multiple disease categories, with particular advances in lymphoma treatment and autoimmune conditions. In follicular lymphoma, rituximab-based regimens remain standard, with epcoritamab combined with lenalidomide and rituximab showing superior outcomes compared to chemoimmunotherapy in relapsed/refractory disease, achieving overall response rates of 96.9% versus 80.5% and superior progression-free survival [PMID 42415230]. Similarly, rituximab maintenance therapy has been associated with improved overall survival in mantle cell lymphoma patients, particularly among those achieving partial remission after induction treatment with R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone), with a hazard ratio for mortality reduction of 0.69 [PMID 41637634]. In follicular lymphoma patients with early disease progression, rituximab-containing regimens, including combinations with lenalidomide and other agents, demonstrated high overall response rates ranging from 87.5% to 100% [PMID 41587420].
Beyond malignancy, rituximab demonstrates efficacy in diverse autoimmune and inflammatory conditions. A single-dose rituximab induction regimen proved effective in an adult patient with IgA vasculitis and rapidly progressive glomerulonephritis despite conventional therapy with glucocorticoids and cyclophosphamide, supporting rituximab's potential in highly active systemic vasculitis [PMID 42050300]. In neurological autoimmune disorders, rituximab has been evaluated in multiple sclerosis and neuromyelitis optica spectrum disorders; comparative data between rituximab and newer agents such as ocrelizumab in relapsing multiple sclerosis are now emerging [PMID 42384870], while in NMOSD, real-world evidence supports rituximab as an effective B-cell depleting therapy [PMID 42044464]. Long-term maintenance therapy with rituximab has also demonstrated efficacy in myelin oligodendrocyte glycoprotein antibody-associated disease, with evidence supporting its use as a relapse-prevention strategy [PMID 41894908]. Additionally, rituximab treatment has been associated with significantly improved cutaneous manifestations in patients with systemic sclerosis [PMID 40971877].
At the mechanistic and technical level, recent studies have elucidated aspects of rituximab's function and clinical application. Research examining CD20 antigen clustering revealed that CD20 dimerization promotes strong and highly selective binding with rituximab, providing insights into the structural basis of its antibody-antigen interactions [PMID 42331022]. Clinical applications of rituximab quantitation have been advanced through rapid mass spectrometry-based methods, enabling absolute protein measurement in human plasma from chronic lymphocytic leukemia patients with high sensitivity [PMID 42113895]. Furthermore, glycoform engineering strategies have been developed to produce rituximab with tailored N-glycosylation profiles, combining plant-based transient expression with in vitro glycoengineering to optimize biopharmaceutical properties [PMID 41643936].